Home › Funds › Defilade Capital Management, L.P. › OCUL
Defilade Capital Management, L.P. position in OCUL
OCULAR THERAPEUTIX INC · Health Care
Defilade Capital Management, L.P. reported holding 1,490,286 shares of OCUL (OCULAR THERAPEUTIX INC) in its Q2 2026 13F filing — a position valued at US$14.6M, representing 1.96% of its reported portfolio and ranking #22 among its reported holdings. Defilade Capital Management, L.P. has disclosed OCUL holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Defilade Capital Management, L.P.'s OCUL position evolved
Defilade Capital Management, L.P. first disclosed a stake in OCUL in Q4 2025 at 681,663 shares (US$8.3M). The position peaked in Q2 2026 at 1,490,286 shares, worth US$14.6M. Across 3 filings, Defilade Capital Management, L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,490,286 shares valued at US$14.6M. Notable position changes include a 118% increase in Q1 2026 (shares rose 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 681.66K | $8.28M | New |
| Q1 2026 | 1.49M | $12.60M | Add |
| Q2 2026 | 1.49M | $14.63M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About OCUL and 13F data
OCUL (OCULAR THERAPEUTIX INC) is a Health Care company. 42 other funds we track also report a position in OCUL — the largest reported positions include Deep Track Capital, LP (US$193.3M), Avoro Capital Advisors LLC (US$123.1M), SUMMER ROAD LLC (US$119.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding OCUL
- Deep Track Capital, LP 19.69M sh · $193.32M · Q2 2026
- Avoro Capital Advisors LLC 12.54M sh · $123.14M · Q2 2026
- SUMMER ROAD LLC 12.21M sh · $119.89M · Q2 2026
- Venrock Adviser, LLC 10.35M sh · $101.61M · Q2 2026
- Logos Global Management LP 5.30M sh · $52.05M · Q2 2026
- DELTEC ASSET MANAGEMENT LLC 2.48M sh · $24.32M · Q2 2026
- Octagon Capital Advisors LP 2.08M sh · $20.38M · Q2 2026
- TCG Crossover Management, LLC 1.65M sh · $16.18M · Q2 2026
- Boxer Capital Management, LLC 1.30M sh · $12.77M · Q2 2026
- Knoll Capital Management, LLC 1.15M sh · $11.30M · Q2 2026
More on Defilade Capital Management, L.P.
FAQ
How long has Defilade Capital Management, L.P. held OCUL?
Defilade Capital Management, L.P. has disclosed OCUL holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Defilade Capital Management, L.P.'s current position in OCUL?
As of Q2 2026, Defilade Capital Management, L.P. holds 1.49M shares of OCUL (OCULAR THERAPEUTIX INC), valued at $14.63M, representing 1.96% of its reported portfolio and ranking #22.
Has Defilade Capital Management, L.P. been buying or selling OCUL?
In the latest 13F filing (Q2 2026), Defilade Capital Management, L.P. held unchanged its position in OCUL. The position peaked in Q2 2026 at 1.49M shares.
Which other funds hold OCUL?
Other major institutional holders of OCUL include Deep Track Capital, LP, Avoro Capital Advisors LLC, SUMMER ROAD LLC, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.